Provention Bio's bispecific antibody boosts gene therapy safety in mice

By The Science Advisory Board staff writers

January 28, 2021 -- Provention Bio has released results from a preclinical proof-of-concept study for its bispecific antibody-based molecule, PRV-3279, conducted in mouse models for Pompe disease.

PRV-3279 is a dual-affinity retargeting (DART) molecule, targeting the B-cell surface proteins CD32B and CD79B. Simultaneous engagement of these receptors, triggers inhibition of B-cell function and suppression of autoantibody production, thereby regulating B cells without causing depletion

In the study, transgenic mice received gene therapy with an adeno-associated virus 9 (AAV9) vector encoding for the enzyme acid-alpha-glucosidase (GAA) gene. Errors in the GAA gene cause Pompe disease. PRV-3279 reduced anti-AAV9 vector antibody levels in a dose-dependent manner. Coadministration of PRV-3279 with gene therapy has the potential to improve the safety and efficacy of gene therapy treatments, according to the firm.

"We believe PRV-3279 has the potential to intercept and prevent the immunogenicity of life-saving gene therapy products and other biotherapeutics," stated Ashleigh Palmer, CEO and co-founder, Provention Bio.

Intravacc completes process development for CVB vaccine candidate
Contract development and manufacturing organization Intravacc reported that it has completed the process development and manufacturing of a polyvalent...
Celiac Disease Foundation, Provention Bio partner on mAb therapeutic
The Celiac Disease Foundation has partnered with Provention Bio to provide clinical trial recruitment for the ongoing phase IIB Proactive Celiac Study,...
Provention Bio, Amgen begin mAb trial for celiac disease
Provention Bio has begun a phase IIB study of PRV-015, an anti-interleukin-15 monoclonal antibody (mAb), in adult patients with nonresponsive celiac disease....

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter